Literature DB >> 16696083

Interphase ribosomal RNA cistron staining in thyroid epithelial cells in Grave's disease, Hashimoto's thyroiditis and benign and malignant tumours of the thyroid gland.

N N Mamaev1, E N Grynyeva, Y V Blagosklonnaya.   

Abstract

Aim-To evaluate the expression of ribosomal cistrons in human thyroid epithelial cells (TECs) of patients with Grave's disease, Hashimoto's thyroiditis and benign and malignant tumours of the thyroid gland.Methods-TEC nucleoli were investigated in fine needle biopsy specimens from 10 controls, 39 patients with Grave's disease, 15 with Hashimoto's thyroiditis, 56 with benign, and 15 with malignant tumours of the thyroid. A one step silver staining method was applied. In most cases serum concentrations of thyroxine and triiodothyronine as well as goitre size were determined. In every case 100 TECs were evaluated for the mean numbers of nucleoli and for the average number of argyrophilic nucleolar organiser regions (AgNORs) per nucleus.Results-NORs were activated in all patients, but not in controls. The numbers of AgNORs in patients with Grave's disease were closely correlated with thyroxine or triiodothyronine, or both, concentrations and with the size of the thyroid. In patients with Hashimoto's thyroiditis about 30% of TECs nucleoli did not contain AgNORs, whereas others were heavily impregnated with silver. Compared with controls and benign tumours, the nucleoli of carcinomatous TECs were larger and irregular in shape. The mean number of AgNORs per nucleus in malignant cells was higher than that in their benign counterparts.Conclusions-The mechanism by which NORs are activated in TECs varies depending on the type of lesion. The higher AgNOR score in TECs from malignant tumours can be used to distinguish them from their benign counterparts.

Entities:  

Year:  1996        PMID: 16696083      PMCID: PMC408067          DOI: 10.1136/mp.49.4.m240

Source DB:  PubMed          Journal:  Clin Mol Pathol        ISSN: 1355-2910


  12 in total

Review 1.  Nucleolar organizer region activity in human chromosomes and interphase nuclei of normal, leukemic, and tumor cells as evaluated by silver staining.

Authors:  N N Mamaev; S E Mamaeva
Journal:  Int Rev Cytol       Date:  1990

Review 2.  Interphase nucleolar organizer regions in cancer cells.

Authors:  M Derenzini; D Ploton
Journal:  Int Rev Exp Pathol       Date:  1991

3.  Slow growth but intense hypertrophy of thyrocytes in long-standing Grave's goitres.

Authors:  M Derwahl; G Huber; H Studer
Journal:  Acta Endocrinol (Copenh)       Date:  1989-09

4.  Gerard Slavin: editor, Journal of Clinical Pathology, 1978-1988.

Authors:  J S Lilleyman
Journal:  J Clin Pathol       Date:  1988-01       Impact factor: 3.411

Review 5.  Molecular basis of thyroid cancer.

Authors:  N R Farid; Y Shi; M Zou
Journal:  Endocr Rev       Date:  1994-04       Impact factor: 19.871

6.  Ag-NOR counting for differentiation of follicular thyroid tumours.

Authors:  A Cör; Z Pajer
Journal:  Pathologica       Date:  1994-06

7.  Diagnostic value of AgNOR staining in follicular cell neoplasms of the thyroid: comparison of evaluation methods and nucleolar features.

Authors:  J Rüschoff; C Prasser; T Cortez; H M Höhne; W Hohenberger; F Hofstädter
Journal:  Am J Surg Pathol       Date:  1993-12       Impact factor: 6.394

8.  AgNOR area in interphase nuclei of human tumours correlates with the proliferative activity evaluated by bromodeoxyuridine labelling and Ki-67 immunostaining.

Authors:  D Trerè; F Farabegoli; A Cancellieri; C Ceccarelli; V Eusebi; M Derenzini
Journal:  J Pathol       Date:  1991-09       Impact factor: 7.996

9.  Fine needle aspiration cytology combined with argyrophilic nucleolar organizer regions (AgNORs) in diagnosis of thyroid neoplasms.

Authors:  W Szot; Z Szybiński; M Zaczek; D Kedra; E Dabroś; K Piotrowska; Z Chłap
Journal:  Endokrynol Pol       Date:  1993       Impact factor: 1.582

10.  Nucleolar organizer regions in follicular tumors of the thyroid.

Authors:  Y Shem-Tov; M Straus; Y P Talmi; L Rath-Wolfsom; Y Zohar; R Gal
Journal:  Head Neck       Date:  1994 Sep-Oct       Impact factor: 3.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.